收藏切换
Evidence-based study on the clinical diagnosis and treatment of congenital amegakaryocytic thrombocytopenia associated with MPL gene mutation
收藏切换
Chunying CHEN, Xiaotian XIE*
World Clinical Drug | 2023, 44(4) : 355 - 361
Less
收藏切换
World Clinical Drug | 2023, 44(4): 355-361
• Article •
Evidence-based study on the clinical diagnosis and treatment of congenital amegakaryocytic thrombocytopenia associated with MPL gene mutation
Full
Chunying CHEN, Xiaotian XIE*
Affiliations
  • Department of Pediatrics, Tongji Hospital of Tongji University, Shanghai 200065, China
Published: 2023-04-10 doi: 10.13683/j.wph.2023.04.010
Outline
收藏切换
Objective

To explore the clinical characteristics of MPL mutation-related congenital amegakaryocytic thrombocytopenia (CAMT).

Methods

Typical cases of CAMT were summarized by referring to the common confirmation method used in rare disease research. A total of 85 cases of clinical data from 46 literatures at home and abroad were collected since 2010. Statistical analysis was performed to show the clinical characteristics and diagnosis and treatment effect of CAMT.

Results

The main characteristics of CAMT were summarized as follows. The proportion of female patients was higher than that of male patients (1.67∶1), the onset age was earlier (average 12.1 months), and the diagnosis age was delayed (average 46 months). These cases mainly presented with skin and mucous membrane hemorrhage, but 22 cases had intracranial hemorrhage, of which 4 cases had intrauterine intracranial hemorrhage. All patients had decreased peripheral blood plaques (1.0×109/L - 83.0×109/L). MPL gene mutation was presented in all patients, including homozygous 52 cases and complex heterozygous 33 cases. There was a significant trend of pancytopenia. The plasma thrombopoietin (TPO) level was significantly increased, with an average of 1 505.8 pg/ml. Non-hematopoietic system abnormalities up to 52%. The only radical treatment is allogeneic hematopoietic stem cell transplantation (allo-HSCT), and TPO agonists are alternative drugs for children lacking allo-HSCT condition.

Conclusion

The onset of CAMT in the neonatal period or early infant without other special manifestations, so it is easy to be misdiagnosed. Almost all CAMTs may progress to triple hemocytosis with typical aplastic anemia. Aitripopal and romisteine can be used as drugs to replace allo-HSCT.

MPL gene mutation  /  congenital amegakaryocytic thrombocytopenia  /  hereditary bone marrow failure syndrome  /  early diagnosis  /  drug therapy
陈春英, 谢晓恬. MPL基因突变相关先天性无巨核细胞性血小板减少症临床诊治循证研究. 世界临床药物, 2023 , 44 (4) : 355 -361 . DOI: 10.13683/j.wph.2023.04.010
Chunying CHEN, Xiaotian XIE. Evidence-based study on the clinical diagnosis and treatment of congenital amegakaryocytic thrombocytopenia associated with MPL gene mutation[J]. World Clinical Drug, 2023 , 44 (4) : 355 -361 . DOI: 10.13683/j.wph.2023.04.010
Year 2023 volume 44 Issue 4
13
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.04.010
  • Receive Date:2021-11-12
  • Online Date:2026-11-18
  • Published:2023-04-10
Article Data
Affiliations
History
  • Received:2021-11-12
  • Revised:2023-03-28
Funding
Affiliations
    Department of Pediatrics, Tongji Hospital of Tongji University, Shanghai 200065, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.04.010
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT